| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Quest Diagnostics, the world's leading provider of diagnostic information services, announced today that it will present results of four studies at the 2018 American Society of Human Genetics Meeting (ASHG), October 16 – 20, 2018 in San Diego (Quest Diagnostics booth 1514). These studies by Quest Diagnostics researchers evaluate a broad range of laboratory technologies and best practices for aiding in genomic sequencing of data for the diagnosis of patients with a broad range of genetic diseases and disorders. These include next generation sequencing (NGS) to detect alpha-thalassemia common deletions, which can affect the body's production of hemoglobin, causing anemia and other blood disorders. Other research describes best practices for identifying clinically relevant gene variants from sequenced genetic data.
At the start of 2018, I put my health (both mental and physical) as a top priority. I have been seeing the results slowly but surely! Exercising daily has made the biggest impact, along with eating with a more healthy intention. If you like to take charge of your own health, I would suggest starting out with daily walks and incorporating a salad into your every day routine. Those are two super-easy ways to improve your general health! I’ve also added several vitamins and supplements to improve different aspects of my health. I recently decided to check in to see if these supplements have impacted my health. Through Health Testing Centers, I purchased an Expanded Vitamin Panel to see what vitamins I may be showing as low or high. I also purchased an Anemia test to see if I may be anemic. With just a few clicks, I added the two lab tests to my cart, choosing which lab I wanted to go to. I chose Quest Diagnostics because there is a location just a short distance from me. There were so many location choices it will be easy to find a lab near you. You can pay with a credit card or even use PayPal. I love the convenience aspect!
Quest Diagnostics, the world's leading provider of diagnostic information services, today announced that its subsidiary, Summit Health Inc., has completed the previously disclosed acquisition of the assets of Hooper Holmes, Inc. d/b/a Provant Health, a provider of employer health and wellness services focused on whole person wellness and care cost management.
Quest Diagnostics announced today the formation of the Global Diagnostics Network (GDN), a partnership with other large labs across the globe for the sharing of diagnostic innovation, information, and services. The initial focus of the new partnership will include collaboration on companion diagnostics, and the creation of an emerging pathogen preparedness network to expedite infectious disease research and response. Additional initiatives are expected to be rolled out based on regional and global priorities. Quest's partners in the new network include Al Borg Medical Laboratories, founded in Saudi Arabia, with labs across the Middle East and Africa; Dasa, based in Brazil; GC Labs, based in South Korea; KingMed Diagnostics, based in Hong Kong with labs across South East Asia; Primary Health Care, based in Australia; and SynLab, based in Germany with labs across Europe and on four continents.
Soot particles from burning fossil fuels increases the risk of mouth cancer, warns new research. The first study of its kind discovered that high levels of fine particulate matter from engines, power stations and factories, and to a lesser extent, ozone, may be key. The findings, published online by the Journal of Investigative Medicine, show that the number of new cases, and deaths from, mouth cancer is increasing in many parts of the world.Study author Dr Michael McPhaul, of Quest Diagnostics in the US said: “The smaller diameter, but larger surface area, of PM2.5 means that it can be relatively easily absorbed while at the same time potentially wreaking greater havoc on the body.”
Quest Diagnostics the world's leading provider of diagnostic information services, announced today that it received the Gold Award in the 2018 Best Employers for Healthy Lifestyles awards from the National Business Group on Health (NBGH). The awards recognized 49 employers that have an exceptional commitment to improving the lives of their employees through their overall well-being, productivity and quality of life. The Gold Award is presented to member companies that have a strong commitment to holistic well-being and related metrics.
Quest Diagnostics says it is taking over lab services that had been provided by Hurley Medical Center at three locations. Quest announced the new arrangement, the financial terms of which were not disclosed, in a news release this week. Hurley spokeswoman Laura Jasso described Quest as Hurley's "transition partner in lab services" after having made the decision to close some sites where it drew blood "throughout the community."
The number of workers testing positive for drugs they’re not supposed to have is declining in South Carolina, according to a new report from the laboratory Quest Diagnostics. Still, a consistently high rate of positive drug tests has exacerbated the state’s labor shortage.
Secaucus-based Quest Diagnostics, a provider of diagnostic information services, announced that it has acquired PhenoPath, a national provider of specialized anatomic pathology (AP) and related services. Based in Seattle, PhenoPath provides AP, molecular oncology and other services that complement and extend those of the company’s Advanced Diagnostics portfolio of services. These include services, such as genetic sequencing and genomic tumor analysis, which require higher-order expertise and skill.
Gov. Phil Murphy was thrilled to join Quest Diagnostics CEO Steve Rusckowski at a ribbon-cutting for Quest’s new headquarters in Secaucus on Thursday morning. Murphy said he hoped that other CEOs would look at Quest, a Fortune 500 company, choosing New Jersey and follow suit. “We have a newfound will, in addition to our natural assets, to use our advantages to their fullest potential,” he said. “I hope that somewhere, the CEO of another forward-looking, innovative company is listening to us and saying, ‘You know what, if New Jersey works for Quest, then I’ve got to look there, too.’” Murphy spoke of the density of the talent pool in the northern region of the state, proximity to New York City, view of the city and transportation in the area. Murphy also hinted at his upcoming economic development trips abroad.
Quest Diagnostics announced today it has acquired specialized anatomic pathology service firm PhenoPath. The deal, whose terms were not disclosed, continued a buying spree for Quest this week, which included the acquisitions of Oxford Immunotec's US lab business and fertility and fertility diagnostics services firm ReproSource. PhenoPath is based in Seattle and provides anatomic pathology, molecular oncology, and other services such as genetic sequencing and genomic tumor analysis. It will operate as part of AmeriPath, a wholly owned subsidiary of Quest.
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Regional Medical Center Health System (RMC), a regional health care provider for a five-county service area in northeast Alabama, are teaming up to enhance the quality and value of diagnostic services to patients and their doctors through a new partnership agreement under which Quest will provide supply chain expertise, as well as perform laboratory reference testing.
Since Colorado legalized marijuana, the state has become a popular destination for so-called weed tourists. Johnny Welsh, a writer and bartender in Frisco, Colorado, a Rocky Mountain town near Vail, remembers when he would have the entire fall off work. "The restaurants closed, and you could travel the world," he told MoneyWatch, somewhat wistfully. Nationwide, the rate of workers testing positive for drugs has increased over the past decade, according to Quest Diagnostics, a major drug-testing laboratory. It has also risen in states that have made the drug legal. But the rate of increase has been about the same across the two categories, said Barry Sample, Quest's senior director for science and technology.
Quest Diagnostics today announced it has acquired fertility diagnostics service firm ReproSource for an undisclosed amount. Based Woburn, Massachusetts, ReproSource provides services such as ovarian health and recurrent pregnancy loss assessments, as well as implantation failure and semen quality. According to the company's website, it purchased the assets of "the largest fertility-focused laboratory in the United States" in 2008, and since then it improved and expanded its core services while establishing partnerships with laboratory, academic, and industry players in the US and globally.
If voters decide in November to legalize marijuana for recreational use, pot-smoking job seekers and employees beware. Legalization will not protect job applicants or employees who test positive for marijuana use on pre-employment drug tests or random workplace drug testing. Yes, you can still get fired or not be hired for a positive test. Unlike alcohol, where Breathalyzer tests can show the exact level in a person’s blood, there are few available tests that show the level of impairment for marijuana. Saliva swabs and urine samples only show if THC, the psychoactive component in marijuana, has been used over the last few days, said Dr. Barry Sample, of Quest Diagnostics, a New Jersey company that analyzes millions of workplace drug tests every year, not a person’s level of impairment at the time of a test. Tests of hair samples will show THC levels going back as long as 90 days.
There has been a trend a recent years for hospitals and health systems to sell their lab outreach businesses, often to one of the two largest commercial reference labs, Quest Diagnostics and LabCorp, and then outsource their lab services to the same company. There is some early evidence that this trend may now be reversing.
There’s no argument that health care is changing: from service-based to value-based care, and from a supplier-centric to a patient-centric model. Both regulatory and patient pressures are pushing for better efficiency, better outcomes and simply better care. These pressures are moving the industry to be more open to the adoption of new technologies, tools and, in many cases, solutions that automate manual processes. These tools are powered by a specialized rocket fuel known as patient data. But in the rush to digitally capture and make the best use of patient data, two primary challenges have arisen. First, how do we break down the information silos that currently exist within our health care system? Secondly, while breaking the silos, how do we protect sensitive patient information as we share it across the health care ecosystem? There is also a large number of other tech-centric businesses and organizations that are currently utilizing blockchain to generate innovative solutions. Even large health care giants such as Humana and Quest Diagnostics have begun their own ventures into the world of blockchain.
As someone who has studied use and misuse of prescription opioids and other drugs for much of my career, I know drug misuse can happen to anyone. I have had friends, relatives and neighbors pulled into misuse, which includes substance-use disorders and other dangerous behaviors, such as drug combining. And I am not alone. A recently released statewide poll found that 1 of 3 adults in Texas knows someone who has been addicted to prescription painkillers. McClure is the director of medical affairs for Quest Diagnostics , the world’s leading provider of diagnostics information services, including in clinical drug monitoring.
Cleveland Clinic's 16th annual Medical Innovation Summit, scheduled for Oct. 22-24 in downtown Cleveland, will center around the theme of "Disruption: Reimagining Healthcare."[CR-LF][CR-LF]The summit — organized by Cleveland Clinic Innovations, the system's development and commercialization arm — is anticipated to gather more than 100 speakers, as well as leaders from more than 500 organizations and 20 countries, according to a news release. It will be held at the Huntington Convention Center. According to the release, other featured speakers include Nigel Clarke, vice president of technology and solutions development for Quest Diagnostics.
Two conflicting trends are hitting the United States: a continuing shortage of qualified or willing candidates for truck driving jobs, and the increasing state-level legalization of medical or recreational marijuana. The two trends certainly don’t mix. David Couch, the Little Rock attorney who wrote the medical marijuana amendment voters approved in 2016, doesn’t want marijuana users driving big rigs any more than the most anti-pot politician does.A recent study by Quest Diagnostics, the national drug testing lab service, reported that overall drug use in the tested workforce is down in Arkansas. The national rate held steady at 4.2 percent of the workforce, while the state rate dropped from 6 percent in 2016 to 5 percent in 2017. The study measured individual drugs as well.
As we first reported last May, Holmes founded the start-up Theranos and boasted her technology could take a pin-prick worth of blood from the finger and perform hundreds of laboratory tests. It was, she claimed, "the most important thing humanity has ever built." At its zenith, Theranos was worth nearly $10 billion and Elizabeth Holmes became the youngest, self-made, female billionaire in the world. Today, she and her company's one-time president stand criminally charged by the U.S. government of perpetrating a "multi-million dollar scheme" to defraud investors, doctors and patients. Elizabeth Holmes built her company Theranos on this invention she named the Edison. A miniaturized blood analyzer that would disrupt the $60 billion lab testing industry dominated by giants LabCorp and Quest Diagnostics.
Although more than half of Americans misuse prescription drugs, the percentage that did so has held steady for four consecutive years, according to a new analysis. Meanwhile, though, there has also been a surge in the use of illicit drugs and medicines obtained without a prescription among patients being treated for substance use disorders.
The countless drops of sweat covering their drenched bodies are indicative of the hard work put in by the New York Giants throughout the hot and humid summer. Those same droplets were also analyzed and examined to help individual performance. The Giants used a new sweat test this year to make sure their players were properly hydrated and prepared for the rigors of summer. It should continue to help them throughout the season. It’s not a completely new idea, just a refined version of a sweat test. There are other teams using different variations of this new patch the Giants had analyzed by Quest Diagnostics as part of their Blueprint for Athletes program. This iteration is easier to implement and is believed to be more effective than the previous processes they have tried over the past few years. The hope is that its benefits can stretch throughout the year and provide even the slightest of competitive advantages.
Prescription data alone underestimated how many patients combined opioids and benzodiazepines, an analysis of Quest Diagnostics drug test data indicated. Among a selected sample of patients whose drug test indicated concurrent benzodiazepine and opioid use, 64% had at least one benzodiazepine or opioid that was not prescribed, according to Quest researcher Leland McClure, PhD, and colleagues in a poster presentation at the 2018 PAINWeek conference.
Genomic Vision, a company specializing in the development of diagnostic tests for the early detection of cancers and hereditary diseases, and applications for life sciences research, today announces the second payment from its collaboration with Quest Diagnostics on biomarker identification of currently undetected “2+0” SMA carriers following the Milestone program signed in 2018. A first Milestone (1a) was reached at the end of 2017, resulting in the design and validation of a new GMC covering with higher precision the complex SMA region. The goal of the second Milestone (1b) consisted in performing complementary experiments and analysis on existing samples in order to identify smaller biomarkers for SMN1 cis-duplication potentially leading to SMA diagnostic test.